Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA sees increase in SPAs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Center for Drug Evaluation and Research is predicting that it will receive roughly 364 special protocol assessment requests from 143 sponsors in 2008, while the Center for Biologics Evaluation and Research estimates that it will receive roughly 10 requests from eight sponsors, according to an Oct. 12 Federal Register notice. Over the last three years, FDA has seen an increase in submissions of special protocol assessments, which were introduced in 2002 to allow companies to reach agreements on trial design with FDA in advance of conducting the study. FDA is working on new procedures that will help streamline the application process and ensure better tracking...

The Center for Drug Evaluation and Research is predicting that it will receive roughly 364 special protocol assessment requests from 143 sponsors in 2008, while the Center for Biologics Evaluation and Research estimates that it will receive roughly 10 requests from eight sponsors, according to an Oct. 12 Federal Register notice. Over the last three years, FDA has seen an increase in submissions of special protocol assessments, which were introduced in 2002 to allow companies to reach agreements on trial design with FDA in advance of conducting the study. FDA is working on new procedures that will help streamline the application process and ensure better tracking....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS003682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel